List of things named after Thomas Bayes

DoseMe Selected as a Pharma 2023 Innovation Award Winner

Retrieved on: 
Wednesday, September 27, 2023

DoseMe , a leading provider of precision dosing software for therapeutic drug monitoring (TDM) today announced its DoseMe Analytics platform was named a winner of the Pharma Innovation Awards.

Key Points: 
  • DoseMe , a leading provider of precision dosing software for therapeutic drug monitoring (TDM) today announced its DoseMe Analytics platform was named a winner of the Pharma Innovation Awards.
  • Pharma Manufacturing , an Endeavor Business Media brand, annually recognizes technologies contributing to advancements in risk reduction, product quality improvement, and manufacturing efficiency.
  • The Pharma Innovation Awards are a tribute to those who listen to the needs of the market and their customers, and as a result, have distinguished themselves as leaders in pharma equipment and technology.
  • “We are honored to be selected along with 12 other incredibly valuable tools that help pharma companies to develop innovative, lifesaving medicines,” stated Paul Edwards, CEO of DoseMe.

Mount Nittany Medical Center Increases Accuracy and Efficiency of Vancomycin Dosing Using InsightRX Model-Informed Precision Dosing Platform

Retrieved on: 
Tuesday, September 19, 2023

SAN FRANCISCO, Sept. 19, 2023 /PRNewswire/ -- InsightRX – which provides cloud-based precision medicine software to optimize treatment decisions – today announced results of a data analysis by Mount Nittany Medical Center showing how deploying InsightRX's Bayesian software integrated with PINC AI™ Clinical Surveillance powered by TheraDoc® for monitoring vancomycin dosing helped increase efficiency and optimized pharmacist workflow compared to industry benchmarks.

Key Points: 
  • Based in State College, Pa., Mount Nittany Health operates Mount Nittany Medical Center, a 260-bed acute care facility with a 24-bed intensive care unit and a 61-bed emergency department (ED).
  • Mount Nittany Medical Center has roughly 55,000 ED visits each year.
  • While there are several ways to calculate AUC, Mount Nittany Medical Center chose to implement Bayesian modeling using InsightRX's model-informed precision dosing (MIPD) software platform.
  • "We are excited by the results of Mount Nittany Medical Center's comparative analysis and look forward to continuing our partnership."

Sarah Bush Lincoln Adopts DoseMe Precision Dosing Platform to Improve Overall Level of Patient Care

Retrieved on: 
Wednesday, September 13, 2023

DoseMe , a leading provider of precision dosing software for therapeutic drug monitoring (TDM) and creators of DoseMeRx and DoseMe Analytics, today announced Sarah Bush Lincoln utilized its precision dosing platform to transition to area under the curve (AUC) dosing for better patient care, upgrading DoseMeRx to integrate directly into their Cerner electronic health record (EHR).

Key Points: 
  • DoseMe , a leading provider of precision dosing software for therapeutic drug monitoring (TDM) and creators of DoseMeRx and DoseMe Analytics, today announced Sarah Bush Lincoln utilized its precision dosing platform to transition to area under the curve (AUC) dosing for better patient care, upgrading DoseMeRx to integrate directly into their Cerner electronic health record (EHR).
  • During drug development, drug level sampling at multiple time points helps define the relationship between drug administration and the AUC.
  • “DoseMeRx’s vancomycin model is the first phase of our precision dosing initiative with pediatric and obesity divisions to follow.
  • Sarah Bush Lincoln has 17 extended campus primary care locations and four walk-in clinics.

PrecisePK Celebrates 30 Years of Bayesian Precision Dosing Partnership With UC San Diego Health, Leading Other UC Hospitals To Follow

Retrieved on: 
Thursday, August 24, 2023

SAN DIEGO, Aug. 24, 2023 /PRNewswire/ -- Today, PrecisePK announces the celebration of the 30th anniversary of its partnership with UC San Diego Health.

Key Points: 
  • SAN DIEGO, Aug. 24, 2023 /PRNewswire/ -- Today, PrecisePK announces the celebration of the 30th anniversary of its partnership with UC San Diego Health.
  • This decades-long initiative has proven the success of using Bayesian precision dosing to improve patient outcomes.
  • With other UC hospitals joining, PrecisePK is delivering state-of-the-art Bayesian therapeutic drug monitoring technology to a total of 9 prominent sites.
  • PrecisePK and UCSD Health mark 30 years of partnership in vancomycin AUC precision dosing, leading others to follow.

DoseMe Expands Leadership Team with Appointments of Paul Edwards to CEO, John Hardesky to CCO and Sharmeen Roy to Chief Strategy & Science Officer

Retrieved on: 
Wednesday, July 12, 2023

DoseMe , a leading provider of precision dosing software for therapeutic drug monitoring and creators of DoseMeRx and DoseMe Analytics, today announced the appointments of Paul Edwards to Chief Executive Officer, John Hardesky to the role of Chief Commercial Officer and Dr. Sharmeen Roy , PharmD, BCPS, to Chief Strategy and Science Officer.

Key Points: 
  • DoseMe , a leading provider of precision dosing software for therapeutic drug monitoring and creators of DoseMeRx and DoseMe Analytics, today announced the appointments of Paul Edwards to Chief Executive Officer, John Hardesky to the role of Chief Commercial Officer and Dr. Sharmeen Roy , PharmD, BCPS, to Chief Strategy and Science Officer.
  • This expansion of the senior leadership team will enable DoseMe to continue to evolve its precision dosing capabilities and ensure it is supporting hospitals and care teams to individualize patient treatment results.
  • Paul Edwards, CEO - Previously Paul held senior executive roles with Merck and GSK, as well as start-ups including ILUM Health Solutions, Infectious Disease Connect, and TrackMy Solutions.
  • John Hardesky, CCO - An accomplished senior leader with over 20 years of commercial experience focused on the global clinical market.

Taysha Gene Therapies Provides Clinical Updates for Investigational Programs TSHA-120 in Giant Axonal Neuropathy (GAN) and TSHA-102 in Rett Syndrome at R&D Day

Retrieved on: 
Wednesday, June 28, 2023

DALLAS, June 28, 2023 (GLOBE NEWSWIRE) --  Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS), announced new data analyses for TSHA-120 in GAN and initial clinical observations for TSHA-102 in Rett syndrome. Taysha will host a virtual R&D Day today at 10:00 AM ET to discuss these updates. The webcast link can be accessed on the Events and Presentations section of Taysha’s website.

Key Points: 
  • Taysha will host a virtual R&D Day today at 10:00 AM ET to discuss these updates.
  • The webcast link can be accessed on the Events and Presentations section of Taysha’s website.
  • We’ve requested a formal FDA meeting to discuss these new developments to support a potential regulatory path forward for TSHA-120.
  • TSHA-102 utilizes a novel miRNA-Responsive Auto-Regulatory Element (miRARE) platform designed to regulate cellular MECP2 expression.

How should a robot explore the Moon? A simple question shows the limits of current AI systems

Retrieved on: 
Wednesday, June 28, 2023

At the heart of their concern is the idea AI might become so powerful we lose control of it.

Key Points: 
  • At the heart of their concern is the idea AI might become so powerful we lose control of it.
  • Ultimately, AI systems should help humans make better, more accurate decisions.
  • And they create incentives to collect huge amounts of data and may encourage a lax attitude to privacy, legal and ethical questions and risks.

Cause, effect and confidence

    • Consequently, they are great at interpolating – that is, predicting or filling in the gaps between known values.
    • It does not generate knowledge, nor the insights necessary for decision-makers operating in complex environments.
    • As a result, they encourage organisations to assemble enormous repositories of data – or trawl through existing datasets collected for other purposes.

From big data to useful information

    • Instead, they need useful information.
    • The usefulness of the information depends on the question at hand, the decisions we face, and the value we attach to the consequences of those decisions.
    • To paraphrase the US statistician and writer Nate Silver, the amount of truth is approximately constant irrespective of the volume of data we collect.

A robot on the Moon

    • The degree of confidence is as important as the belief, because it is a measure of what the robot doesn’t know.
    • The robot lands and faces a decision: which way should it go?
    • The robot goes to its new location, records observations using its sensors, and updates its belief and associated confidence.

Mapping unknown landscapes

    • Their jobs involve exploring and mapping unknown social or economic landscapes.
    • Suppose we wish to develop policies to encourage all children to thrive at school and finish high school.
    • We need a conceptual map of which actions, at what time, and under what conditions, will help to achieve these goals.

Learning as we go

    • As new information comes to hand, new actions are chosen to maximise some pre-specified criteria.
    • Where AI can be useful is in identifying what information is most valuable, via algorithms that quantify what we don’t know.
    • Automated systems can also gather and store that information at a rate and in places where it may be difficult for humans.
    • We do need to reform our laws and create new rules to guide the use of potentially dangerous AI systems.

The Hershey Company selects marketing analytics company in4mation insights, LLC, for Media Mix Modeling to help unlock future growth

Retrieved on: 
Wednesday, June 14, 2023

in4mation insights LLC, a MA-based leading innovator in media optimization and the practical application of Hierarchical Bayesian models and The Hershey Company, are pleased to announce a multi-year strategic partnership for media mix modeling & optimization tools and services.

Key Points: 
  • in4mation insights LLC, a MA-based leading innovator in media optimization and the practical application of Hierarchical Bayesian models and The Hershey Company, are pleased to announce a multi-year strategic partnership for media mix modeling & optimization tools and services.
  • in4mation insights will leverage its advanced Bayesian analytics tools to develop modern, customized media mix models that will help address the evolving challenges in media and to transform decision making at Hershey.
  • The Hershey Company will also utilize in4mation insights‘ new state-of-the-art simulation & optimization tool, Optimetry™.
  • We feel we’re setting ourselves up for the next phase of growth across the Hershey Company and our iconic brands for our current and future commercial capabilities."

INmune Bio Inc.’s Chief Scientific Officer, Mark Lowdell, Ph.D. to Present Plenary Talk at International Society of Cell & Gene Therapy

Retrieved on: 
Wednesday, May 24, 2023

The Company believes this is a critical breakthrough to avoid the complications associated with cytokine therapy and obtain NK cells ideally suited for attacking cancer.

Key Points: 
  • The Company believes this is a critical breakthrough to avoid the complications associated with cytokine therapy and obtain NK cells ideally suited for attacking cancer.
  • Using high-dimensional flow cytometry to simultaneously analyze 31 cell surface proteins, the team analyzed resting NK cells, IL-15 LAK (LAK=lymphokine activated killer cells), CIML-NK and INKmune-primed (TpNK) side-by-side.
  • The data showed at least 8 clusters of NK cell types, one of which was restricted to CIML-NK and TpNK.
  • CIML-NK contains a large population of terminally activated cells with loss of spare respiratory activity, which is absent from TpNK.

Kern Medical Chooses PrecisePK to Provide Bayesian Precision Dosing Solutions

Retrieved on: 
Thursday, May 25, 2023

SAN DIEGO, May 25, 2023 /PRNewswire/ -- Today, PrecisePK welcomes Kern Medical as its latest institution to implement innovations in precision dosing for vancomycin and other antibiotics using the Bayesian AUC-based method.

Key Points: 
  • SAN DIEGO, May 25, 2023 /PRNewswire/ -- Today, PrecisePK welcomes Kern Medical as its latest institution to implement innovations in precision dosing for vancomycin and other antibiotics using the Bayesian AUC-based method.
  • This recent alliance with Kern Medical adds to the system-wide endeavor of accomplishing personalized and precision dosing with a modernized approach by leveraging technology.
  • Kern Medical's vancomycin dosing workflow is standardized and improved by PrecisePK's Bayesian precision dosing tools.
  • With Bayesian precision dosing, it's more than the right dose for the right patient at the right time.